Skip to content
Sign in
Artwork for BioSpace
ScienceLife Sciences

BioSpace

BioSpace

Unravel the business of science with BioSpace. We dive into biopharma's top stories and biggest challenges, whether it’s layoffs, pipeline shake-ups, acquisitions, new FDA approvals or how to regulate AI in drug development.

Play
Open in
  • 41 episodes
  • Avg 21 min
  • English

Episodes 41

NewestOldestLongest
All20Unplayed20In progress0Played0
Counted on this page — what you have heard stays on this device, so it is not something the list can be paged by.
  • Today · 22 min

    Beyond equity: Why venture debt is reshaping European biotech

    In this episode of Denatured, you’ll hear from Jennifer McMahon, partner at Seroba and Joey Mason, venture partner at Claret Capital. We dig into how venture debt buys time when equity can’t — and how Europe’s funding gaps, tranching habits and slower urgency shape who uses it well. Host Jennifer C. Smith-Parker, Director of Insights, BioSpace Guests Jennifer McMahon, Partner, Seroba Joey Mason, Venture Partner, Claret Capital Disclaimer: The views expressed in this discussion by guests are their own and do not represent those of their organizations.

    • Transcript
  • Yesterday · 24 min

    Genmab and AbbVie’s Epkinly win, a rush of deals, Sarepta’s turnaround hopes, more

    New data for Genmab and AbbVie’s bispecific antibody Epkinly wowed analysts and could set the partners up for an expanded approval in diffuse large B cell lymphoma; deals have flowed steadily this week, including Novartis’ nearly $8 billion bet on mRNA drugs with China’s Abogen Biosciences; and could Sarepta Therapeutics turn things around from last year’s annus horribilis?

    • Transcript
  • October 1 · 20 min

    The race for access: How the FAIR Act could reclaim U.S. biotech leadership

    In this episode of Denatured, you’ll hear from Max Bronstein, CEO of Aviva Strategies and Teresa Barnes, Chief Executive Warrior of PF Warriors. We dig into why U.S. patients are losing access to rare disease trials happening abroad and how the FAIR Act’s accelerated, harmonized reviews could help the U.S. keep pace while getting lifesaving studies to patients faster. Host ⁠Jennifer C. Smith-Parker, Director of Insights, BioSpace Guests Max Bronstein, CEO, Aviva Strategies Teresa Barnes, Chief Executive Warrior, PF Warriors Disclaimer: The views expressed in this discussion by guests are their own and do not represent those of their organizations.

    • Transcript
  • September 30 · 20 min

    AstraZeneca buys into Summit, UniQure drops on 4-year data, FDA on a roll

    Summit Therapeutics scores a $2 billion equity investment from AstraZeneca to support ivonescimab’s late-stage development; uniQure crashes after four-year data from its Huntington’s disease gene therapy failed to impress; Kyverna Therapeutics brings new light to a struggling CAR T space in autoimmune disease.

    • Transcript
  • September 24 · 15 min

    How radioligand therapy is rewriting cancer care

    In this episode of Denatured presented by Curium, Jennifer Smith-Parker speaks to Mike Patterson, CEO North America and Professor Sabine Brookman-May, vice president and head of Global Clinical Development. We examine radioligand therapy’s accelerating momentum and how its diagnostic and therapeutic reach could potentially reshape care for more than 14 million patients worldwide. We also discuss Curium's push to expand US capacity and scale up at pace, and critically what success could mean for patients with cancer in the years ahead. This episode is presented in partnership with Curium. Host Jennifer Smith-Parker, Director of Insights, BioSpace Guests Mike Patterson, CEO North America, Curium Sabine Brookman-May, VP and Head of Global Clinical Development, Curium Disclaimer: The views expressed in this discussion by guests are their own and do not represent those of their organizations.

    • Transcript
  • September 23 · 21 min

    Novo’s turnaround plan, weight loss wins, Ultragenyx’s Sanfilippo approval, IPO blitz

    Novo plans to hit $23B in revenue by 2035, has further reduced its workforce by 4,000 and is boosting manufacturing capacity for its Wegovy pill, but investors are unconvinced it will be enough to turn things around; Viking Therapeutics and Roche report positive results for their weight loss assets; Ultragenyx snags FDA approval for its Sanfilippo syndrome gene therapy; IPOs keep on coming.

    • Transcript
  • September 17 · 21 min

    When vision fades: Rethinking wet AMD and the durability gap

    In this episode of Denatured, you’ll hear Philip Jacob Rosenfeld, professor of Ophthalmology at the University of Miami Health System and Bascom Palmer Eye Institute, and Wesley Jackson, chief science officer at Valitor. We talk about the eye condition call wet age-related macular degeneration (AMD), the limits of anti‑VEGF therapy and the push for true durability to change a patient’s life. Host Jennifer C. Smith-Parker, Director of Insights, BioSpace Guests Philip Jacob Rosenfeld, Professor of Ophthalmology, University of Miami Health System, Bascom Palmer Eye Institute Wesley Jackson, Chief Science Officer, Valitor Disclaimer: The views expressed in this discussion by guests are their own and do not represent those of their organizations.

    • Transcript
  • September 16 · 22 min

    FDA hears input on psychedelics, PDUFA, lung cancer’s next-gen therapies boost survival

    The FDA held a public forum on Monday to discuss the future of psychedelic therapeutics, followed by a meeting on Wednesday regarding recommendations for reauthorizing the Prescription Drug User Fee Act the day after launching its TrialBlazer initiative. Meanwhile, Definium Therapeutics notched another late-stage trial win for its LSD drug, and Novartis continues to reel from the company’s triple asset stumble.

    • Transcript
  • September 10 · 36 min

    The supply chain fault lines of modern pharma

    In this episode of Denatured, sponsored by SK Pharmteco, Jennifer Smith-Parker speaks to Arvind Singh, vice president and global head of supply chain. In this episode, we discuss how CDMOs are revamping supply‑chain strategy for a new generation of intricate modalities. Topics addressed include moving from smarter raw‑material sourcing and precision cold‑chain logistics to navigating geopolitical and regulatory uncertainty and deploying AI to building sustainable, scalable capabilities from clinical through commercial. This episode is presented in partnership with SK Pharmteco. Host Jennifer Smith-Parker, Director of Insights, BioSpace Guest Arvind Singh, VP & Global Head of Supply Chain Disclaimer: The views expressed in this discussion by guests are their own and do not represent those of their organizations.

    • Transcript
  • September 9 · 20 min

    Novo’s canned heart disease trials, Novartis’ clinical fails, first approval for Alexander disease

    September has been a rough month already for Novo Nordisk, which canned two more late-stage trials of its embattled IL-6 inhibitor, and Novartis, which took Phase 3 hits in both cardiovascular and muscular dystrophy indications; Ultragenyx’s big bet in Angelman syndrome failed to yield benefit in Phase 3 but Ionis’ Pharmaceuticals nabbed the first targeted approval for Alexander disease; and on the business side, biopharma investment is back in a big way.

    • Transcript
  • September 3 · 18 min

    Breaking borders: Building biotech scale in Benelux

    In this episode of Denatured, you’ll listen to Christina Takke, managing partner at V-Bio Ventures and Mariette van der Velden-Roesink, founding partner at Curie Capital. We examine why Benelux delivers world‑class science yet remains an investment patchwork, and what it will take to knit the region into a truly unified biotech investment corridor. Host ⁠Jennifer C. Smith-Parker, Director of Insights, BioSpace Guests Christina Takke, Managing Partner, V-Bio Ventures Mariette van der Velden-Roesink, Founding Partner, Curie Capital Disclaimer: The views expressed in this discussion by guests are their own and do not represent those of their organizations.

    • Transcript
  • September 2 · 20 min

    Novartis’ and BMS’ paused CAR T trials, RevMed’s pancreatic cancer approval, more MFN deals

    Novartis hits pause on several CAR T trials after three patient deaths, followed by Bristol Myers Squibb after separate safety signals; Revolution Medicines scores early FDA approval for groundbreaking pancreatic cancer drug; BioNTech suspends a mid-stage trial of its mRNA cancer immunotherapy after a futility analysis; and nine mid-sized biopharma companies join their big pharma peers in President Donald Trump’s Most Favored Nation drug pricing scheme.

    • Transcript
  • August 27 · 19 min

    Fragile X at a turning point: Breaking through the clinical bottleneck

    In this episode of Denatured, you’ll hear from Hilary Rosselot, executive director at the National Fragile X Foundation and Jordi Fàbrega, co-founder & CEO at CONNECTA Therapeutics. From trial endpoints and placebo effects to neuroplasticity modulation, we explore what it will take to build a sustainable path to the first approved therapy. Host Jennifer C. Smith-Parker, Director of Insights, BioSpace Guests Hilary Rosselot, Executive Director, National Fragile X Foundation Jordi Fàbrega, Co-Founder & CEO, CONNECTA Therapeutics Disclaimer: The views expressed in this discussion by guests are their own and do not represent those of their organizations.

    • Transcript
  • August 26 · 23 min

    Capricor’s DMD therapy still alive, Merck/Moderna’s cancer vax shines, FDA’s future revealed

    FDA extends its review of Capricor Therapeutics’ Duchenne muscular dystrophy cell therapy as an unhappy shareholder advocates for change; Merck and Moderna tout positive data for their mRNA-based cancer vaccine; Trump nominates White House aide Heidi Overton as FDA commissioner; and the oral obesity market heats up with rivals Eli Lilly and Novo Nordisk going head-to-head.

    • Transcript
  • August 20 · 19 min

    Rewriting the rules of CMV prevention

    In this episode of Denatured, you’ll hear from Ian McGowan, Chief Medical Officer at Synklino and James Hunter, associate professor of transplantation at Oxford University. We explore transplantation and antiviral innovation and why CMV remains one of the most persistent and consequential challenges facing transplant patients today. Host Jennifer C. Smith-Parker, Director of Insights, BioSpace Guests Ian McGowan, CMO, Synklino James Hunter, Associate Professor of Transplantation, Oxford University Disclaimer: The views expressed in this discussion by guests are their own and do not represent those of their organizations. Custom Fields

    • Transcript
  • August 19 · 19 min

    Amylyx’s redemption story, Summit’s survival woes, Definium’s anxiety win, more

    Amylyx shares good news for its investigational GLP-1 blocker; Definium announces positive data for its LSD-based therapy in anxiety; Summit/Akeso’s ivonescimab shows degrading survival benefits; patients treated with Neurocrine’s Prader-Willi drug experience serious adverse events; and Eli Lilly cracks down on the black market for next-gen obesity asset retatrutide.

    • Transcript
  • August 13 · 18 min

    The Italian inflection point: Clinical strength, culture and capital

    In this episode of Denatured, you’ll hear from Diana Saraceni, founder and managing partner at Panakès Partners and Fabrizio Calisti, medical director at Angelini Ventures. We explore how Italy’s life sciences ecosystem has evolved over the last decade—from stronger tech transfer and growing venture capital to the gaps that still keep it from matching the UK, Germany or France in company creation and scale. Host Jennifer C. Smith-Parker, Director of Insights, BioSpace Guests Diana Saraceni, Founder and Managing Partner, Panakès Partners Fabrizio Calisti, Medical Director, Angelini Ventures Disclaimer: The views expressed in this discussion by guests are their own and do not represent those of their organizations.

    • Transcript
  • August 11 · 23 min

    Rumors of biggest pharma merger ever drop amid Q2 earnings, contentious FDA adcomms

    The industry has been abuzz since the weekend when talks of a potential mega-merger between Bristol Myers Squibb and AstraZeneca were reported. Meanwhile, Pfizer, Merck and others release second quarter earnings, with some disclosing pipeline discontinuations and cost-cutting measures. Finally, all eyes turn to the FDA in the wake of heated advisory committee meetings for Capricor Therapeutics and Replimune.

    • Transcript
  • August 6 · 20 min

    The next treatment-resistant depression paradigm

    In this episode of Denatured, you’ll hear from Hans Eriksson, chief medical officer at FundaMental Pharma and Steve Levine, chief patient officer at Compass Pathways. We explore why treatment-resistant depression remains so difficult to address, and how new approaches—from rapid-acting antidepressants to psychedelic therapy—may reshape the treatment paradigm. Host ⁠Jennifer C. Smith-Parker, Director of Insights, BioSpace Guests Hans Eriksson, Chief Medical Officer, FundaMental Pharma Steve Levine, Chief Patient Officer, Compass Pathways Disclaimer: The views expressed in this discussion by guests are their own and do not represent those of their organizations.

    • Transcript
Showing 1–20 of 41 episodes